Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study

BACKGROUND: Trastuzumab has been introduced a decade ago and demonstrated improvement in the prognosis in patients with human epidermal growth factor receptor 2- (HER2-) positive (+) breast carcinoma (BC). This study is aimed at evaluating the efficacy of epirubicin/cyclophosphamide with weekly pacl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mengmeng, Li, Ling, Zhang, Shiyong, Zhu, Wenlong, Yang, Senguo, Di, Guangsheng, Ma, Xiaoxia, Yang, Haisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222597/
https://www.ncbi.nlm.nih.gov/pubmed/32461977
http://dx.doi.org/10.1155/2020/3208391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222597/
https://www.ncbi.nlm.nih.gov/pubmed/32461977
http://dx.doi.org/10.1155/2020/3208391

Ejemplares similares